Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region

Author:

Han Kelong1ORCID,Ito Hiroshi2,Elston Robert3,Cremer Jennifer4,Hood Steve3,Paff Melanie1,Theodore Dickens4

Affiliation:

1. GSK, Collegeville, Pennsylvania, USA

2. GSK K.K., Tokyo, Japan

3. GSK, Stevenage, United Kingdom

4. GSK, Durham, North Carolina, USA

Abstract

GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few studies have examined ASOs in Asian participants.

Funder

GlaxoSmithKline

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference24 articles.

1. World Health Organization. 2021. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed 25 January 2021.

2. Hepatitis B infection in the general population of China: a systematic review and meta-analysis

3. World Health Organization. 2017. Global hepatitis report 2017. https://www.who.int/publications/i/item/9789241565455. Accessed 25 January 2021.

4. New Approaches to the Treatment of Chronic Hepatitis B

5. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3